Amgen Inc. buy melinda
Start price
31.08.17
/
50%
€159.06
Target price
12.09.17
€171.38
Performance (%)
7.96%
End price
12.09.17
€171.72
Summary
This prediction ended on 12.09.17 with a price of €171.72. The BUY prediction by melinda finished with a performance of 7.96%. melinda has a follow-up prediction for Amgen Inc. where he still thinks Amgen Inc. is a Buy. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Amgen Inc. | 1.589% | 1.589% | 17.696% | 41.571% |
| iShares Core DAX® | 2,90 % | 3,65 % | 5,76 % | 49,36 % |
| iShares Nasdaq 100 | 4,60 % | 3,06 % | 36,95 % | 89,09 % |
| iShares Nikkei 225® | 10,42 % | 12,61 % | 64,98 % | 72,73 % |
| iShares S&P 500 | 2,57 % | 1,36 % | 25,17 % | 65,39 % |
Comments by melinda for this prediction
In the thread Amgen Inc. diskutieren
zu folgen
$
Wenn in Phase III getestet Kopf an Kopf, das Bestreben, reduziert KYPROLIS und Dexamethason das Sterberisiko um 21% und erhöhte die Überlebenszeit von 7,6 Monaten im Vergleich zu Velcade und Dexamethason in Patienten mit rezidivierendem oder refraktärem multiplem Myelom